-$0.24 EPS Expected for Xenon Pharmaceuticals Inc (NASDAQ:XENE) This Quarter

Share on StockTwits

Wall Street brokerages forecast that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will announce earnings per share (EPS) of ($0.24) for the current quarter, Zacks reports. Four analysts have made estimates for Xenon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.11). Xenon Pharmaceuticals reported earnings of ($0.37) per share during the same quarter last year, which would indicate a positive year over year growth rate of 35.1%. The firm is expected to announce its next earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($1.15) to ($0.61). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.38) per share, with EPS estimates ranging from ($2.13) to ($0.11). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, May 21st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.10. The company had revenue of $7.08 million during the quarter, compared to analyst estimates of $7.50 million.

A number of equities analysts recently commented on the company. BidaskClub downgraded Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 29th. Zacks Investment Research downgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Wedbush started coverage on Xenon Pharmaceuticals in a report on Tuesday, March 24th. They set an “outperform” rating and a $23.00 price objective on the stock. William Blair reissued a “buy” rating on shares of Xenon Pharmaceuticals in a report on Friday, May 22nd. Finally, Jefferies Financial Group started coverage on shares of Xenon Pharmaceuticals in a research report on Sunday, May 31st. They issued a “buy” rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $21.25.

XENE stock traded up $0.39 during mid-day trading on Monday, hitting $13.20. The stock had a trading volume of 104,969 shares, compared to its average volume of 266,771. The company has a fifty day moving average of $12.90 and a 200 day moving average of $13.54. Xenon Pharmaceuticals has a 1-year low of $7.00 and a 1-year high of $18.45. The stock has a market capitalization of $448.02 million, a price-to-earnings ratio of -9.89 and a beta of 1.31.

In related news, CEO Simon N. Pimstone sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $13.99, for a total transaction of $69,950.00. Following the transaction, the chief executive officer now owns 258,186 shares of the company’s stock, valued at $3,612,022.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Simon N. Pimstone sold 3,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $14.43, for a total transaction of $43,290.00. Following the transaction, the chief executive officer now directly owns 258,186 shares in the company, valued at approximately $3,725,623.98. The disclosure for this sale can be found here. Insiders own 7.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Deutsche Bank AG increased its holdings in shares of Xenon Pharmaceuticals by 2,933.8% during the 1st quarter. Deutsche Bank AG now owns 95,080 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 91,946 shares during the period. BlackRock Inc. bought a new position in Xenon Pharmaceuticals during the first quarter valued at about $87,000. Two Sigma Investments LP increased its stake in Xenon Pharmaceuticals by 15.3% during the first quarter. Two Sigma Investments LP now owns 88,605 shares of the biopharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 11,788 shares during the period. Engineers Gate Manager LP bought a new position in Xenon Pharmaceuticals during the first quarter valued at about $185,000. Finally, BVF Inc. IL increased its stake in Xenon Pharmaceuticals by 11.9% during the fourth quarter. BVF Inc. IL now owns 1,949,075 shares of the biopharmaceutical company’s stock valued at $25,552,000 after acquiring an additional 207,475 shares during the period. Institutional investors own 79.24% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Further Reading: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.